

**UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK**

In re:

PURDUE PHARMA L.P., *et al.*,

Debtors.¹

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered)

**FORTY-SECOND MONTHLY FEE STATEMENT OF FTI CONSULTING, INC. FOR
COMPENSATION FOR SERVICES RENDERED AND REIMBURSEMENT OF
EXPENSES INCURRED AS FINANCIAL ADVISOR TO THE AD HOC COMMITTEE
OF GOVERNMENTAL AND OTHER CONTINGENT LITIGATION CLAIMANTS FOR
THE PERIOD FROM MARCH 1, 2023 THROUGH MARCH 31, 2023**

Name of Applicant:	FTI Consulting, Inc.
Authorized to provide Professional Services to:	Ad Hoc Committee of Governmental and Other Contingent Litigation Claimants
Date of Order Approving Debtors' Payment of Fees and Expenses of Applicant:	December 2, 2019 [ECF No. 553]
Period for which compensation and reimbursement is sought:	March 1, 2023 through March 31, 2023
Monthly Fees Incurred:	\$91,292.50

1. The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifesciences Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717), and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

Monthly Expenses Incurred: \$0.00

Total Fees and Expenses Due: \$91,292.50

This is a: X monthly _____interim _____final application

PRIOR APPLICATIONS:

Docket No./Filed	Compensation Period	Requested		Approved	
		Fees	Expenses	Fees	Expenses
Docket No. 635 Filed On 12/9/2019	9/19/2019 – 10/31/2019	\$778,791.50	\$680.61	\$771,291.50	\$680.61
Docket No. 741 Filed On 1/13/2020	11/1/2019 – 11/30/2019	\$827,575.00	\$899.41	\$820,075.00	\$899.41
Docket No. 852 Filed on 2/20/2020	12/1/2019 – 12/31/2019	\$802,036.50	\$2,284.19	\$794,536.50	\$2,284.19
Docket No. 916 Filed on 3/12/2020	1/1/2020 – 1/31/2020	\$774,662.00	\$11,530.84	\$767,162.00	\$11,530.84
Docket No. 1090 Filed on 4/27/2020	2/1/2020 – 2/29/2020	\$615,089.00	\$6,141.22	\$610,714.00	\$6,141.22
Docket No. 1171 Filed on 5/19/2020	3/1/2020 – 3/31/2020	\$561,863.50	\$67.08	\$557,488.50	\$67.08
Docket No. 1251 Filed on 6/10/2020	4/1/2020 – 4/30/2020	\$428,303.00	\$1,732.28	\$423,928.00	\$1,732.28
Docket No. 1379 Filed on 7/13/2020	5/1/2020 – 5/31/2020	\$303,367.00	\$4,325.26	\$298,992.00	\$4,325.26
Docket No. 1651 Filed on 9/2/2020	6/1/2020 – 6/30/2020	\$374,753.00	\$96.90	\$372,253.00	\$ 96.90
Docket No. 1725 Filed on 9/25/2020	7/1/2020 – 7/31/2020	\$446,975.50	\$0.00	\$444,475.50	\$0.00
Docket No. 1850 Filed on 10/26/2020	8/1/2020 – 8/31/2020	\$261,092.00	\$108.25	\$258,592.00	\$108.25
Docket No. 1950 Filed on 10/26/2020	9/1/2020 – 9/30/2020	\$357,546.50	\$0.00	\$355,046.50	\$0.00
Docket No. 2031 Filed on 11/24/2020	9/19/2019 – 9/30/2020	\$44,462.00	\$0.00	\$41,462.60	\$0.00
Docket No. 2154 Filed on 12/18/2020	10/1/2020 – 10/31/2020	\$356,078.50	\$0.00	\$353,078.50	\$0.00
Docket No. 2308 Filed on 1/20/2021	11/1/2020 – 11/30/2020	\$450,827.00	\$0.00	\$447,827.00	\$0.00
Docket No. 2503 Filed on 3/17/2021	12/1/2020 – 12/31/2020	\$308,146.00	\$0.00	\$305,146.00	\$0.00
Docket No. 2504 Filed on 3/17/2021	1/1/2021 – 1/31/2021	\$493,773.50	\$0.00	\$490,773.50	\$0.00
Docket No. 2848 Filed on 5/12/2021	2/1/2021 – 2/28/2021	\$381,199.00	\$9.99	\$377,458.99	\$9.99
Docket No. 2849 Filed on 5/12/2021	3/1/2021 – 3/31/2021	\$513,645.00	\$0.00	\$509,895.00	\$0.00
Docket No. 3017 Filed on 6/11/2021	4/1/2021 – 4/30/2021	\$415,904.00	\$0.00	\$412,154.00	\$0.00
Docket No. 3225 Filed on 7/15/2021	5/1/2021 – 5/31/2021	\$363,711.00	\$40.00	\$360,001.00	\$40.00
Docket No. 3747 Filed on 9/9/2021	6/1/2021 – 6/30/2021	\$303,427.50	\$0.00	\$299,677.50	\$0.00

PRIOR APPLICATIONS (cont.):

Docket No./Filed	Compensation Period	Requested		Approved	
		Fees	Expenses	Fees	Expenses
Docket No. 3798 Filed on 9/21/2021	7/1/2021 – 7/31/2021	\$431,630.50	\$135.81	\$427,880.50	\$135.81
Docket No. 3941 Filed on 10/14/2021	8/1/2021 – 8/31/2021	\$284,159.00	\$20.94	\$280,409.00	\$20.94
Docket No. 4097 Filed on 11/11/2021	9/1/2021 – 9/30/2021	\$244,958.50	\$0.00	\$241,208.50	\$0.00
Docket No. 4225 Filed on 12/15/2021	10/1/2021 – 10/31/2021	\$368,998.50	\$40.00	\$367,498.50	\$40.00
Docket No. 4311 Filed on 1/26/2022	11/1/2021 – 11/30/2021	\$255,094.50	\$1,160.04	\$253,594.50	\$1,160.04
Docket No. 4312 Filed on 1/26/2022	12/1/2021 – 12/31/2021	\$192,786.50	\$0.00	\$191,286.50	\$0.00
Docket No. 4395 Filed on 2/25/2022	1/1/2022 – 1/31/2022	\$314,564.00	\$0.00	\$313,064.00	\$0.00
Docket No. 4654 Filed on 4/12/2022	2/1/2022 – 2/28/2022	\$181,198.50	\$8.00	\$178,888.84	\$8.00
Docket No. 4826 Filed on 5/16/2022	3/1/2022 – 3/31/2022	\$267,504.00	\$44.03	\$265,194.33	\$44.03
Docket No. 4833 Filed on 5/16/2022	4/1/2022 – 4/30/2022	\$175,704.00	\$0.00	\$173,394.33	\$0.00
Docket No. 4950 Filed on 7/12/2022	5/1/2022 – 5/31/2022	\$98,099.50	\$0.00	\$96,849.50	\$0.00
Docket No. 5005 Filed on 8/8/2022	6/1/2022 – 6/30/2022	\$53,624.00	\$0.00	\$52,374.00	\$0.00
Docket No. 5051 Filed on 8/31/2022	7/1/2022 – 7/31/2022	\$53,023.00	\$0.00	\$51,773.00	\$0.00
Docket No. 5132 Filed on 10/12/2022	8/1/2022 – 8/31/2022	\$35,470.00	\$0.00	\$34,220.00	\$0.00
Docket No. 5240 Filed on 11/15/2022	9/1/2022 – 9/30/2022	\$53,219.00	\$8.00	\$52,344.00	\$8.00
Docket No. 5341 Filed on 1/13/2023	10/1/2022 – 10/31/2022	\$30,107.50	\$0.00	\$29,232.50	\$0.00
Docket No. 5342 Filed on 1/13/23	11/1/2022 – 11/30/2022	\$31,105.00	\$0.00	\$30,230.00	\$0.00
Docket No. 5393 Filed on 2/1/23	12/1/2022 – 12/31/2022	\$42,190.00	\$0.00	\$41,315.00	\$0.00
Docket No. 5518 Filed on 3/30/23	1/1/2023 – 1/31/2023	\$98,523.50	\$0.00	\$78,818.80	\$0.00
Docket No. 5519 Filed on 3/30/23	2/1/2023 – 2/28/2023	\$125,875.00	\$0.00	\$100,700.00	\$0.00

Note: The fee examiner's agreed upon reductions of \$30,000, \$17,500, \$10,000, \$15,000, \$15,000, \$15,000, \$6,000, \$6,929, \$5,000, and \$3,500 were allocated evenly across fees from the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, and tenth interim period, respectively.

This statement (the “**Fee Statement**”) of FTI Consulting, Inc. (together with its wholly owned subsidiaries and independent contractors, “**FTI**”) as financial advisor to the Ad Hoc Committee of Governmental and Other Contingent Litigation Claimants of Purdue Pharma L.P., *et al.* (the “**Committee**”) is submitted in accordance with the *Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Retained Professionals* [ECF No. 529] and the *Order Authorizing the Debtors to Assume the Reimbursement Agreement and Pay the Fees and Expenses of the Ad Hoc Committee’s Professionals* [ECF No. 553] entered on November 21, 2019 and December 2, 2019, respectively, (the “**Orders**”). In support of this Fee Statement, FTI respectfully states as follows.

1. The fees and expenses for the period from March 1, 2023 through and including March 31, 2023 (the “**Fee Period**”) amount to:

Professional Fees	\$91,292.50
Expenses	<u>0.00</u>
TOTAL	<u>\$91,292.50</u>

2. If no timely and proper objection is made by a party-in-interest within fourteen (14) days after service of this Fee Statement, the Debtors are authorized to pay 80% of professional fees and 100% of out-of-pocket expenses. These amounts are presented below.

Professional Fees at 80%	\$73,034.00
Expenses at 100%	<u>0.00</u>
TOTAL	<u>\$73,034.00</u>

3. The professionals providing services, hourly billing rates, the aggregate hours worked by each professional, and the aggregate hourly fees for each professional during the Fee Period are set forth on the schedule annexed hereto as **Exhibit “A”**.
4. A summary of aggregate hours worked and aggregate hourly fees for each task code during the Fee Period is set forth on the schedule annexed hereto as **Exhibit “B”**.

5. Detailed time entry by task code during the Fee Period is set forth on the schedule annexed hereto as **Exhibit “C”**.
6. FTI reserves the right to request, in subsequent fee statements and applications, reimbursement of any additional expenses incurred during the Fee Period, as such expenses may not have been captured to date in FTI’s billing system.

NOTICE AND OBJECTION PROCEDURES

7. Objections to this Fee Statement, if any, must be filed with the Court and served upon the Notice Parties so as to be received no later than May 26, 2023 (the “**Objection Deadline**”), setting forth the nature of the objection and the amount of fees or expenses at issue (an “**Objection**”).
8. If no objections to this Fee Statement are filed and served as set forth above, the Debtors shall promptly pay eighty percent (80%) of the fees and one hundred percent (100%) of the expenses identified herein.
9. If an objection to this Fee Statement is received on or before the Objection Deadline, the Debtors shall withhold payment of that portion of this Fee Statement to which the objection is directed and promptly pay the remainder of the fees and disbursements in the percentages set forth above. To the extent such an objection is not resolved, it shall be preserved and scheduled for consideration at the next interim fee application hearing to be heard by the Court.

Dated: New York, New York
May 12, 2023

FTI CONSULTING, INC.
Financial Advisors to the Ad Hoc Committee of
Governmental and Other Contingent Litigation
Claimants of Purdue Pharma L.P.

By: /s/ Matthew Diaz
Matthew Diaz, Senior Managing Director
1166 Avenue of the Americas, 15th Floor
New York, New York 10036
Telephone: (212) 499-3611
Email: matt.diaz@fticonsulting.com

EXHIBIT A

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
SUMMARY OF HOURS BY PROFESSIONAL
FOR THE PERIOD MARCH 1, 2023 TO MARCH 31, 2023

Professional	Position	Specialty	Billing Rate	Total Hours	Total Fees
Diaz, Matthew	Sr Managing Director	Restructuring	\$ 1,325	21.8	\$ 28,885.00
Bromberg, Brian	Sr Director	Restructuring	975	37.9	36,952.50
Kurtz, Emma	Sr Consultant	Restructuring	750	17.6	13,200.00
Blittner, Jack	Consultant	Restructuring	475	25.8	12,255.00
GRAND TOTAL				103.1	\$ 91,292.50

EXHIBIT B

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
SUMMARY OF HOURS BY TASK
FOR THE PERIOD MARCH 1, 2023 TO MARCH 31, 2023

Task Code	Task Description	Total Hours	Total Fees
1	Current Operating Results & Events	7.5	\$ 4,922.50
2	Cash & Liquidity Analysis	0.6	795.00
7	Analysis of Domestic Business Plan	22.7	20,352.50
9	Analysis of Employee Comp Programs	22.3	19,047.50
13	Analysis of Other Miscellaneous Motions	8.0	8,140.00
16	Analysis, Negotiate and Form of POR & DS	26.4	26,060.00
21	General Mtgs with Counsel and/or Ad Hoc Committee	4.1	4,227.50
24	Preparation of Fee Application	11.5	7,747.50
GRAND TOTAL		103.1	\$ 91,292.50

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD MARCH 1, 2023 TO MARCH 31, 2023

Task Category	Date	Professional	Hours	Activity
1	3/2/2023	Blittner, Jack	0.3	Prepare the 3/2 daily update email to the internal FTI team regarding docket updates, dataroom filings, and news updates.
1	3/3/2023	Blittner, Jack	0.3	Prepare the 3/3 daily update email to the internal FTI team regarding docket updates, dataroom filings, and news updates.
1	3/4/2023	Diaz, Matthew	0.9	Review January MOR to assess company's performance.
1	3/6/2023	Blittner, Jack	0.4	Prepare the 3/6 daily update email to the internal FTI team regarding docket updates, dataroom filings, and news updates.
1	3/7/2023	Blittner, Jack	0.4	Prepare the 3/7 daily update email to the internal FTI team regarding docket updates, dataroom filings, and news updates.
1	3/8/2023	Blittner, Jack	0.2	Prepare the 3/8 daily update email to the internal FTI team regarding docket updates, dataroom filings, and news updates.
1	3/9/2023	Blittner, Jack	0.6	Prepare the 3/9 daily update email to the internal FTI team regarding docket updates, dataroom filings, and news updates.
1	3/10/2023	Blittner, Jack	0.4	Prepare the 3/10 daily update email to the internal FTI team regarding docket updates, dataroom filings, and news updates.
1	3/13/2023	Blittner, Jack	0.4	Prepare the 3/13 daily update email to the internal FTI team regarding docket updates, dataroom filings, and news updates.
1	3/14/2023	Blittner, Jack	0.4	Prepare the 3/14 daily update email to the internal FTI team regarding docket updates, dataroom filings, and news updates.
1	3/16/2023	Blittner, Jack	0.3	Prepare the 3/16 daily update email to the internal FTI team regarding docket updates, dataroom filings, and news updates.
1	3/17/2023	Blittner, Jack	0.2	Prepare the 3/17 daily update email to the internal FTI team regarding docket updates, dataroom filings, and news updates.
1	3/20/2023	Blittner, Jack	0.3	Prepare the 3/20 daily update email to the internal FTI team regarding docket updates, dataroom filings, and news updates.
1	3/22/2023	Blittner, Jack	0.4	Prepare the 3/22 daily update email to the internal FTI team regarding docket updates, dataroom filings, and news updates.
1	3/23/2023	Blittner, Jack	0.2	Prepare the 3/23 daily update email to the internal FTI team regarding docket updates, dataroom filings, and news updates.
1	3/24/2023	Blittner, Jack	0.2	Prepare the 3/24 daily update email to the internal FTI team regarding docket updates, dataroom filings, and news updates.
1	3/28/2023	Blittner, Jack	0.1	Prepare the 3/28 daily update email to the internal FTI team regarding docket updates, dataroom filings, and news updates.
1	3/28/2023	Diaz, Matthew	0.7	Review the February MOR report to assess the Debtors' recent financial performance.
1	3/29/2023	Blittner, Jack	0.2	Prepare the 3/29 daily update email to the internal FTI team regarding docket updates, dataroom filings, and news updates.
1	3/30/2023	Blittner, Jack	0.3	Prepare the 3/30 daily update email to the internal FTI team regarding docket updates, dataroom filings, and news updates.
1	3/31/2023	Blittner, Jack	0.3	Prepare the 3/31 daily update email to the internal FTI team regarding docket updates, dataroom filings, and news updates.
1 Total			7.5	
2	3/21/2023	Diaz, Matthew	0.6	Review updated cash flow report to assess the Debtors' liquidity status.
2 Total			0.6	
7	3/1/2023	Bromberg, Brian	0.4	Review recent business plan information received from the Debtors' to assess operational performance.
7	3/2/2023	Bromberg, Brian	0.4	Review R&D spending amounts to incorporate into latest business plan analysis.
7	3/2/2023	Bromberg, Brian	0.8	Review latest business plan received from the Debtors' to assess next steps.
7	3/6/2023	Bromberg, Brian	1.1	Review PHI spend to assess potential financial implications.
7	3/6/2023	Bromberg, Brian	0.3	Review updated business plan analysis to provide feedback to the team.
7	3/6/2023	Diaz, Matthew	0.3	Review PHI spend to assess next steps.
7	3/7/2023	Bromberg, Brian	0.8	Prepare for call with the Debtors' professionals re: business plan updates.
7	3/7/2023	Bromberg, Brian	0.7	Participate in call with the Debtors' professionals re: business plan updates and key case issues.
7	3/7/2023	Diaz, Matthew	0.7	Participate in call with the Debtors' professionals re: key case issues and business plan updates.
7	3/7/2023	Kurtz, Emma	0.7	Participate in call with the Debtors' professionals re: case status and business plan updates.
7	3/10/2023	Bromberg, Brian	1.2	Review PHI expense issues to assess next steps.
7	3/10/2023	Bromberg, Brian	0.7	Prepare draft PHI expense summary to provide update to the internal team.

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD MARCH 1, 2023 TO MARCH 31, 2023

Task Category	Date	Professional	Hours	Activity
7	3/10/2023	Diaz, Matthew	0.9	Review proposed correspondence to the Debtors' professionals re: PHI spend analysis.
7	3/10/2023	Diaz, Matthew	0.6	Participate in a call with Alix re: PHI spend and projections.
7	3/11/2023	Bromberg, Brian	0.4	Prepare responses to questions from the internal team re: PHI spend analysis.
7	3/13/2023	Blittner, Jack	1.9	Develop PHI historical spend variance analysis.
7	3/13/2023	Blittner, Jack	1.3	Incorporate updates into the PHI historical analysis based on feedback from the team.
7	3/13/2023	Blittner, Jack	0.6	Continue to incorporate updates into the PHI historical analysis based on feedback from the team.
7	3/13/2023	Bromberg, Brian	0.9	Review 2021 and 2023 business plan analysis to assess the Debtors' financial performance.
7	3/13/2023	Bromberg, Brian	0.3	Review strategic alternative business plan materials to assess potential implications for the Committee.
7	3/13/2023	Bromberg, Brian	0.6	Continue to review 2021 and 2023 business plan analysis to assess the Debtors' financial performance.
7	3/14/2023	Blittner, Jack	1.2	Prepare updates to PHI historical comparable analysis per comments from team.
7	3/14/2023	Bromberg, Brian	1.2	Review analysis of historical PHI spend and projections to provide comments.
7	3/14/2023	Bromberg, Brian	0.6	Update draft letter to the Debtors re: PHI spend.
7	3/14/2023	Kurtz, Emma	0.3	Review historical PHI comparable analysis to provide feedback to team.
7	3/15/2023	Blittner, Jack	0.7	Prepare historical R&D analysis in preparation for upcoming call with the Committee.
7	3/15/2023	Bromberg, Brian	0.9	Finalize 2021 and 2023 business plan analysis re: R&D spend.
7	3/15/2023	Bromberg, Brian	0.6	Participate in call with the Debtors' professionals re: Avrio sale updates.
7	3/15/2023	Diaz, Matthew	0.6	Prepare correspondence to the Debtors' professionals re: HRT analysis.
7	3/17/2023	Diaz, Matthew	0.6	Review analysis of historical PHI and R&D spend to evaluate trends.
7	3/21/2023	Bromberg, Brian	0.4	Review updated business plan to evaluate changes in R&D and PHI forecasts.
7 Total			22.7	
9	3/6/2023	Blittner, Jack	0.9	Analyze 2022 scorecard results to prepare presentation for the Committee.
9	3/6/2023	Blittner, Jack	1.6	Incorporate updates to 2022 scorecard analysis based on feedback from the team.
9	3/6/2023	Blittner, Jack	0.4	Prepare additional updates to 2023 scorecard presentation.
9	3/6/2023	Bromberg, Brian	1.4	Review KEIP scorecard support files to provide feedback to the team.
9	3/6/2023	Bromberg, Brian	0.4	Review KEIP analysis to provide feedback to the team.
9	3/6/2023	Diaz, Matthew	0.4	Review the proposed 2022 scorecard results received from the Debtors.
9	3/6/2023	Kurtz, Emma	1.8	Review 2022 KEIP scorecard to prepare revisions to KEIP slides.
9	3/12/2023	Bromberg, Brian	0.6	Review PHI scorecard information to provide update to the internal team.
9	3/13/2023	Blittner, Jack	1.4	Prepare analysis of 2022 and 2023 scorecard objectives from the Debtors' professionals.
9	3/13/2023	Bromberg, Brian	0.8	Review PHI scorecard presentation to provide feedback to the team.
9	3/13/2023	Kurtz, Emma	0.6	Review PHI scorecards for 2022 and 2023 to prepare comparable analysis.
9	3/13/2023	Kurtz, Emma	0.9	Provide guidance to team re: PHI scorecard comparison year over year.
9	3/13/2023	Kurtz, Emma	0.7	Review draft presentation re: 2023 scorecard metrics to provide comments.
9	3/16/2023	Blittner, Jack	0.9	Update analysis of 2022 and 2023 scorecard objectives to reflect comments received from the team.
9	3/16/2023	Bromberg, Brian	1.4	Review 2023 scorecard objectives to identify key compensation issues.
9	3/21/2023	Bromberg, Brian	1.3	Review updated slides summarizing employee scorecard analysis to provide comments.
9	3/21/2023	Diaz, Matthew	0.3	Review slides summarizing employee scorecard analysis to provide feedback to the internal team.
9	3/22/2023	Bromberg, Brian	0.8	Review updated scorecard analysis to provide additional comments to the internal team.
9	3/23/2023	Bromberg, Brian	0.8	Prepare updated 2023 employee scorecard proposed changes.
9	3/23/2023	Bromberg, Brian	0.6	Review responses received from the Debtors re: employee scorecard questions.
9	3/23/2023	Diaz, Matthew	0.4	Review proposed scorecard changes to evaluate updates.
9	3/24/2023	Bromberg, Brian	0.6	Prepare correspondence with Counsel re: proposed employee scorecard recommendation.
9	3/24/2023	Diaz, Matthew	0.3	Review recommended changes to 2023 employee scorecard.
9	3/27/2023	Bromberg, Brian	0.4	Review employee scorecard analysis and proposal in preparation for upcoming call with the Debtors' professionals.
9	3/27/2023	Bromberg, Brian	0.7	Prepare summary of scorecard issues to provide update to counsel.
9	3/27/2023	Bromberg, Brian	0.7	Participate in call with the Debtors' professionals re: employee scorecard objectives and proposal.
9	3/27/2023	Diaz, Matthew	0.2	Review updated scorecard provisions in preparation for upcoming call with the Debtors' professionals.
9	3/27/2023	Diaz, Matthew	0.7	Participate in call with the Debtors' professionals re: employee scorecard objectives and recommendation.

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD MARCH 1, 2023 TO MARCH 31, 2023

Task Category	Date	Professional	Hours	Activity
9	3/29/2023	Bromberg, Brian	0.3	Prepare correspondence with Counsel re: proposed 2023 scorecard objectives received from the Debtors.
9 Total			22.3	
13	3/1/2023	Blittner, Jack	0.8	Review updated HRT motion to evaluate request.
13	3/1/2023	Bromberg, Brian	0.7	Review HRT motion to potential implications for the Committee.
13	3/4/2023	Diaz, Matthew	0.8	Review HRT funding motion to assess next steps.
13	3/4/2023	Diaz, Matthew	0.7	Review prior presentation the committee re: HRT funding request.
13	3/6/2023	Bromberg, Brian	0.3	Review HRT funding motion to provide update to the internal team.
13	3/6/2023	Diaz, Matthew	0.6	Review HRT responses in connection with the funding motion.
13	3/6/2023	Diaz, Matthew	0.7	Review updated HRT motion to assess next steps.
13	3/7/2023	Blittner, Jack	0.9	Prepare slides summarizing latest HRT funding motion in preparation for upcoming call with the Committee.
13	3/7/2023	Bromberg, Brian	0.7	Review slides summarizing HRT funding issues to provide feedback to the team.
13	3/8/2023	Bromberg, Brian	1.2	Finalize slides summarizing the latest HRT motion in preparation for upcoming call with the Committee.
13	3/14/2023	Diaz, Matthew	0.6	Review updated HRT funding analysis to provide feedback to the team.
13 Total			8.0	
16	3/1/2023	Kurtz, Emma	0.9	Review comments received from Houlihan Lokey re: distributable value analysis to identify necessary updates.
16	3/2/2023	Bromberg, Brian	0.4	Review comments received from Houlihan Lokey re: distributable value analysis.
16	3/2/2023	Kurtz, Emma	1.8	Prepare revisions to distributable value model and accompanying presentation per internal comments.
16	3/3/2023	Bromberg, Brian	1.8	Review changes to distributable value model reflecting latest assumptions.
16	3/6/2023	Bromberg, Brian	1.3	Review updated distribution analysis to provide feedback to the team.
16	3/6/2023	Bromberg, Brian	0.6	Review updated distribution analysis presentation to provide feedback to the team.
16	3/6/2023	Diaz, Matthew	1.8	Review updated NOAT/MDT projected cash flows to assess next steps.
16	3/6/2023	Kurtz, Emma	1.1	Prepare revisions to distributable value model and accompanying slides to reflect comments from team.
16	3/6/2023	Kurtz, Emma	1.7	Incorporate extended disposition case into distributable value model and accompanying slides.
16	3/7/2023	Blittner, Jack	1.1	Prepare slides summarizing distributable value analysis in preparation for upcoming call with the Committee.
16	3/7/2023	Blittner, Jack	0.3	Incorporate revisions to distributable value presentation per internal comments.
16	3/7/2023	Bromberg, Brian	1.4	Review updated distributable value analysis presentation to provide additional comments to the team.
16	3/7/2023	Diaz, Matthew	0.6	Review updated distributable analysis to provide additional feedback to the team.
16	3/7/2023	Diaz, Matthew	0.8	Review updated projected emergence cash flow analysis to assess potential implications for the Committee.
16	3/7/2023	Kurtz, Emma	0.9	Prepare further revisions to update deck re: distributable value analysis.
16	3/8/2023	Bromberg, Brian	0.4	Finalize slides summarizing distribution value analysis in preparation for upcoming call with the Committee.
16	3/8/2023	Bromberg, Brian	0.9	Review memo received from Counsel to assess strategic alternatives.
16	3/8/2023	Diaz, Matthew	1.2	Continue to review updated projected emergence cash flow analysis to assess potential implications for the Committee.
16	3/9/2023	Bromberg, Brian	0.3	Review analysis of strategic alternatives to evaluate plan options.
16	3/9/2023	Diaz, Matthew	0.9	Review presentation received from Counsel re: strategic alternatives.
16	3/17/2023	Blittner, Jack	0.2	Update slides summarizing the distributable value to reflect comments received from the team.
16	3/17/2023	Bromberg, Brian	0.7	Review updated slides summarizing the distributable value analysis to provide additional feedback to the team.
16	3/21/2023	Bromberg, Brian	0.6	Participate in call with the Debtors' professionals re: key case issues, upcoming deliverables, business plan updates, and emergence preparation.
16	3/21/2023	Diaz, Matthew	0.6	Participate in call with the Debtors' professionals re: key case issues and upcoming deliverables.
16	3/21/2023	Kurtz, Emma	0.6	Participate in call with the Debtors' professionals re: key case updates, upcoming deliverables, and emergence preparation.
16	3/22/2023	Bromberg, Brian	0.3	Review updated distributable value analysis to provide additional comments to the internal team.

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD MARCH 1, 2023 TO MARCH 31, 2023

Task Category	Date	Professional	Hours	Activity
16	3/24/2023	Bromberg, Brian	0.4	Review slides summarizing distribution value analysis in preparation for upcoming call with the AHC.
16	3/24/2023	Bromberg, Brian	1.0	Participate in a call with the AHC re: distributable value analysis.
16	3/24/2023	Diaz, Matthew	1.0	Participate in a call with the AHC re: distributable value analysis.
16	3/24/2023	Diaz, Matthew	0.8	Review distributable value analysis to prepare for call with the AHC.
16 Total			26.4	
21	3/8/2023	Bromberg, Brian	0.8	Review materials to prepare for presentation to the AHC re: distributable value analysis and HRT funding motion.
21	3/9/2023	Bromberg, Brian	1.0	Participate in call with the AHC re: distributable value analysis, HRT funding motion, and other key case updates.
21	3/9/2023	Diaz, Matthew	0.3	Prepare for call with the AHC re: strategic alternatives.
21	3/9/2023	Diaz, Matthew	1.0	Participate in call with the AHC re: strategic alternatives, distributable value analysis, and other key case updates.
21	3/9/2023	Kurtz, Emma	1.0	Participate in call with the AHC re: distributable value analysis and other key case updates.
21 Total			4.1	
24	3/11/2023	Kurtz, Emma	2.1	Prepare draft January fee application per local rules.
24	3/14/2023	Diaz, Matthew	0.6	Review draft January fee statement.
24	3/20/2023	Blittner, Jack	3.3	Prepare draft February fee application per local rules.
24	3/20/2023	Blittner, Jack	0.6	Continue to prepare draft February fee application per fee examiner guidelines.
24	3/20/2023	Kurtz, Emma	0.4	Review February fee application.
24	3/21/2023	Blittner, Jack	0.6	Update February fee application.
24	3/21/2023	Kurtz, Emma	0.9	Review draft February fee application.
24	3/22/2023	Blittner, Jack	1.2	Finalize February fee application.
24	3/22/2023	Diaz, Matthew	0.6	Review draft February fee application.
24	3/22/2023	Kurtz, Emma	0.8	Review updated draft of February fee application.
24	3/30/2023	Kurtz, Emma	0.4	Finalize January and February fee applications to be filed.
24 Total			11.5	
Grand Total			103.1	